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studies and the results of multiple studies performed in different
regions play an important role in helping to give a scale to the
quality of care in infectious diseases, especially for deadly dis-
eases. However, this poses different problems. The ﬁrst problem
is that the quality of management is very different from one place
to another. As an example, for the treatment of endocarditis, a
shortened delay for surgery and the intrinsic quality of the sur-
geon are probably the main elements in the survival rate of pa-
tients [1]. Indeed, most centres with efﬁcient results for the
treatment of endocarditis have an extremely high proportion of
patients treated by early surgery. There is also a linear correlation
between the surgery rate and the survival rate evaluated at 3
months. These studies evaluated primarily the network man-
agement quality between infectious disease, cardiac surgery and
specialist cardiologists. This is obviously not globalizable.
The second point is compliance, including the doctor’s
compliance. Patients are often treated successively with three
or four lines of antibiotics without stringent documentation of
the failures. Is the failure a result of an abscess or a further
healthcare-associated complication rather than being an anti-
biotic failure? This is frequently caused by a lack of clear and
simple protocols applied by experienced doctors without
subjectivity.
Patient compliance is also one of the more frequent causes
of failure, as recently observed in pre-exposure chemopro-
phylaxis for human immunodeﬁciency virus (HIV). A study
published in the New England Journal of Medicine included 2499
HIV-seronegative men or transgender women who have sex
with men who were receiving a combination of antiretroviral
drugs or placebo. The authors observed a 44% reduction in the
incidence of HIV in the group treated with antiretroviral drugs
versus placebo and a high compliance documented by serum
dosage levels [2]. Conversely, other studies, performed amongClinical Microbiology and Infection © 2015 European Society of CAfrican women do not demonstrate such efﬁciency but the
compliance was low [3,4]. Consequently, as for management
quality, compliance cannot be globalized.
In the experience of one of the authors (DR), when the
clinician explains comprehensively the side effects and the po-
tential deadly consequences of non-observance, the compliance
rate increases dramatically. As an example, very few patients
followed by DR and treated with a combination of doxycycline
and hydroxychloroquine for Tropheryma whipplei and Coxiella
burnetii infections have photosensitization, although our refer-
ence centre is frequently contacted by clinicians because their
patients are intolerant to such treatment. The repetition of
explanations during each consultation and the persuasive power
of each clinician are key elements in promoting compliance.
Interestingly, in oncology, where clinicians have a culture of
strictly following protocols, we do not observe as much
switching between drugs, despite frequently severe side effects.
Overall, compliance is a major element in the management of
patients with infectious diseases that should be systematically
evaluated before reaching the conclusion of ‘failure’ [5]. Further-
more, the lack of compliance is cultural in some populations and
compliance depends on the age, sex, culture and geographic
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